FibroBiologics
NASDAQ: FBLGHouston, US · Founded 2021 · Delaware corporation
Find your way into FibroBiologics
165 people in our graph share verified history with the FibroBiologics team — schools, employers, funds. One of them is your warm intro.
Peter Mintununlockedknows Pete O'Heeron · together at University of Chicago (overlapped)
×9knows the team · via University of Houston
×2knows the team · via University of Chicago
FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.
Founders & leadership
FibroBiologics was founded in 2021 by Pete O'Heeron.
PO
Pete O'HeeroninChairman/CEO/FounderPete O'Heeron is the founder and CEO of FibroBiologics, a clinical-stage biotech company developing fibroblast cell-based therapies for chronic and degenerative diseases. He has over 25 years of experience in biopharmaceutical development, with more than 400 patents issued or pending in biologics, cell therapy, and medical devices.
JD
Jason D. DavisinChief Financial OfficerJason D. Davis has over 25 years of executive and finance experience, including five years at a Big Four accounting firm and roles at PE-backed and public companies where he led two NYSE and two Nasdaq IPOs and raised more than $200 million in public capital markets; he holds a CPA credential.
RA
Ruben A. GarciainGeneral Counsel
HK
Hamid KhojaChief Scientific Officer
Board
SC
Stacy CoenBoard director
ML
Matthew LinkBoard director
RH
VN
Victoria NiklasBoard director
RC
Richard C. CilentoBoard director
KH
Kathleen H. RubinsBoard director
LS
Leigh SteinbergBoard director
Reported raises · per SEC filings
Form D private placements$10.7M disclosed across 5 of 6 rounds · 2024–2026
▶$500KraisedSep 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedSep 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pete O'HeeronExecutive Officer, Director
- Richard C. CilentoDirector
- Robert HoffmanDirector
- Victoria NiklasDirector
- Kathleen H. RubinsDirector
- Leigh SteinbergDirector
- Jason D. DavisExecutive Officer
- Ruben A. GarciaExecutive Officer
- Hamid KhojaExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3MraisedJun 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJun 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert HoffmanDirector
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Victoria NiklasDirector
- Matthew LinkDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $315K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.7MraisedDec 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert HoffmanDirector
- Matthew LinkDirector
- Stacy CoenDirector
- Jason D. DavisExecutive Officer
- Pete O'HeeronExecutive Officer, Director
- Richard C. CilentoDirector
- Victoria NiklasDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Sales commissions
- $329.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$4MraisedDec 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedDec 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Stacy CoenDirector
- Victoria NiklasDirector
- Matthew LinkDirector
- Robert HoffmanDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedDec 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stacy CoenDirector
- Matthew LinkDirector
- Robert HoffmanDirector
- Victoria NiklasDirector
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Sales commissions
- $292.2K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with FibroBiologics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $252K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets — TradingView Newstradingview.com · Jul 2026
FibroBiologics (NASDAQ: FBLG) discloses going-concern and Nasdaq bid-price risksstocktitan.net · Jul 2026Frequently asked questions
- What does FibroBiologics do?
- FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.
- Who founded FibroBiologics?
- FibroBiologics was founded by Pete O'Heeron in 2021.
- How much funding has FibroBiologics raised?
- FibroBiologics has disclosed $10.7M raised across 5 of its 6 known rounds.
- Where is FibroBiologics headquartered?
- FibroBiologics is headquartered in Houston, US.